Inhibikase Presents Update on Parkinson’s Disease Treatment Trial
Parkinson’s disease remains one of the most prevalent neurodegenerative diseases worldwide, affecting more than one million people in the US alone. Inhibikase Therapeutics (Nasdaq: IKT) is developing risvodetinib for the treatment of Parkinson’s disease through its 201 Trial and will present an update at the 2024 AD/PD conference being held in Lisbon, Portugal this week.
Commenting on the company’s clinical progress, Inhibikase President and Chief Executive Officer, Dr. Milton Werner, said, “The 201 Trial evaluating three doses of risvodetinib in untreated Parkinson’s patients is beginning to yield information about the experience of participants on risvodetinib. While the trial is ongoing, we remain blinded to which participants are administered risvo. Twenty-five people have completed the 12 week dosing course and all have indicated interest to continue into the 12 month extension study when available.”
Highlights
Inhibikase’s 201 Trial is evaluating 50, 100 and 200 mg once daily doses of risvo in untreated Parkinson’s disease.
The trial has 32 sites open and actively evaluating prospective trial participants. 59 participants have been enrolled and 25 have completed the 12 week dosing period.
The company expects to deliver top line results from the 201 Trial reported in the second-half of 2024.
About Inhibikase
Inhibikase Therapeutics, Inc. (Nasdaq: IKT) is a clinical-stage pharmaceutical company developing therapeutics for Parkinson’s disease and related disorders. Inhibikase’s multi-therapeutic pipeline has a primary focus on neurodegeneration and its lead program risvodetinib, a selective inhibitor of the non-receptor Abelson Tyrosine Kinases (c-Abl), targets the treatment of Parkinson’s disease inside and outside the brain as well as other diseases that arise from Ableson Tyrosine Kinases. Its multi-therapeutic pipeline is pursuing Parkinson’s-related disorders of the brain and GI tract, orphan indications related to Parkinson’s disease such as Multiple System Atrophy, and drug delivery technologies for kinase inhibitors such as IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate, that the Company believes will provide a better patient experience with fewer on-dosing side-effects. The Company’s RAMP™ medicinal chemistry program has identified a number of follow-on compounds to risvodetinib that could potentially be applied to other cognitive and motor function diseases of the brain. Inhibikase is headquartered in Atlanta, Georgia with offices in Lexington, Massachusetts.
